Login to Your Account



Clinic Roundup


Friday, December 21, 2012
• Merrimack Pharmaceuticals Inc., of Cambridge, Mass., enrolled its first patient in a study of biomarkers in advanced colorectal, lung and triple-negative breast cancer for estimating delivery of compound MM-398 to tumors and for patient response to the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription